Background Long‐term clinical effectiveness of biologics in psoriasis is needed. Objectives
We aimed to assess the long‐term persistence of biologics used to treat psoriasis in a real …

Background Psoriasis often requires lifelong therapy, and adherence to treatment is
considered a marker for treatment success. Data on the drug survival of biologics in …

Importance Patients with psoriasis enrolled in clinical trials of biologics may not be
representative of the real-world population. There is evidence that patients ineligible for …

Introduction Treatment with biologics often leads to clearance of psoriasis. However, some
patients do repeatedly fail to respond and/or lose an achieved response (treatment …

John Libbey Eurotext - European Journal of Dermatology - Psoriasis vulgaris in a hepatitis B
virus carrier successfully treated with secukinumab and entecavir combination therapy John …

We have read with great interest the articles by Bardazzi et al.(1) and Conforti et al.(2)
discussing whether it is advisable or not to stop biologic treatment in psoriasis patients …

Background The cardiovascular safety profile of biologic therapies used for psoriasis is
unclear. Objectives To compare the risk of major cardiovascular events (CVE s; acute …

Background Drug survival depends on several factors such as dosing, effectiveness, quality‐
of‐life improvement and safety, and could be seen as an overall marker for treatment …

Abstract Background Biological therapies (BTs) including infliximab (IFX), adalimumab
(ADL), secukinumab (SCK) and ustekinumab (UST) are approved in Japan for the treatment …

Background A considerable disease period often precedes initiation of a biologic in patients
with psoriasis. Little is known about this important period in patients' lives. Evaluation of this …